Roxtrim may be available in the countries listed below.
Sulfamethoxazole is reported as an ingredient of Roxtrim in the following countries:
Trimethoprim is reported as an ingredient of Roxtrim in the following countries:
International Drug Name Search
Homeopathic remedy provides relief for allergic dermatitis caused by
bee stings, flea, bug, ant and insect bites. Helps relieve itching and promote
healing of irritated scabs, sores and hive-like red spots.
Dosage:
1-20lbs/5 drops 3 times daily.
21-60lbs/10 drops 3 times daily.
61-100lbs/15 drops 3 times daily.
Over 100lbs/20 drops 3 times daily.
Pets Under 1lb, 2 drops in water 3 times daily.
Remedy may be dosed directly into mouth, on food/treat or in water.
When symptoms improve, reduce dosing to twice, then once daily.
When symptoms clear up, discontinue use. If symptoms reappear repeat
the original dose.
Visit www.homeopet.com for detailed dosing and information.
Contact Veterinarian if problems persist.
Ingredients HPUS:
Urtica Urens, Rhus Toxicodendron, Pulex Irritans, Staphysagria,
Sulphur 6c and 30c
Alcohol, Purified Water
| Bug Bites urtica urens, rhus toxicodendron, pulex irritans, staphysagria, sulphur liquid | |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| unapproved homeopathic | 04/15/1995 | ||
| Labeler - HomeoPet, LLC (121272657) |
| Registrant - HomeoPet, LLC (121272657) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Washington Homeopathic Products, Inc. | 084929389 | manufacture | |
Rasermox may be available in the countries listed below.
Amoxicillin is reported as an ingredient of Rasermox in the following countries:
International Drug Name Search
Orozamudol may be available in the countries listed below.
Tramadol hydrochloride (a derivative of Tramadol) is reported as an ingredient of Orozamudol in the following countries:
International Drug Name Search
Rozy-DSR may be available in the countries listed below.
Domperidone is reported as an ingredient of Rozy-DSR in the following countries:
Rabeprazole sodium salt (a derivative of Rabeprazole) is reported as an ingredient of Rozy-DSR in the following countries:
International Drug Name Search
Opipramol-Isis may be available in the countries listed below.
Opipramol dihydrochloride (a derivative of Opipramol) is reported as an ingredient of Opipramol-Isis in the following countries:
International Drug Name Search
Novo-Ampicillin may be available in the countries listed below.
Ampicillin trihydrate (a derivative of Ampicillin) is reported as an ingredient of Novo-Ampicillin in the following countries:
International Drug Name Search
Acularen may be available in the countries listed below.
Ketorolac tromethamine (a derivative of Ketorolac) is reported as an ingredient of Acularen in the following countries:
International Drug Name Search
In the US, Boniva (ibandronate systemic) is a member of the drug class bisphosphonates and is used to treat Osteoporosis and Prevention of Osteoporosis.
US matches:
Ibandronic Acid sodium salt monohydrate (a derivative of Ibandronic Acid) is reported as an ingredient of Boniva in the following countries:
International Drug Name Search
Climesse may be available in the countries listed below.
Estradiol 17ß-valerate (a derivative of Estradiol) is reported as an ingredient of Climesse in the following countries:
Norethisterone is reported as an ingredient of Climesse in the following countries:
International Drug Name Search
Paroxetina Ur may be available in the countries listed below.
Paroxetine hydrochloride (a derivative of Paroxetine) is reported as an ingredient of Paroxetina Ur in the following countries:
International Drug Name Search
Clozix may be available in the countries listed below.
Clozapine is reported as an ingredient of Clozix in the following countries:
International Drug Name Search
Vitamine B12 Gerda may be available in the countries listed below.
Cyanocobalamin is reported as an ingredient of Vitamine B12 Gerda in the following countries:
International Drug Name Search
Famotidin Genericon may be available in the countries listed below.
Famotidine is reported as an ingredient of Famotidin Genericon in the following countries:
International Drug Name Search
Estreptomicina Richet may be available in the countries listed below.
Streptomycin sulfate (a derivative of Streptomycin) is reported as an ingredient of Estreptomicina Richet in the following countries:
International Drug Name Search
Rowadermat may be available in the countries listed below.
Carbenoxolone disodium salt (a derivative of Carbenoxolone) is reported as an ingredient of Rowadermat in the following countries:
International Drug Name Search
PMS-Desmopressin may be available in the countries listed below.
Desmopressin acetate (a derivative of Desmopressin) is reported as an ingredient of PMS-Desmopressin in the following countries:
International Drug Name Search
Riscord may be available in the countries listed below.
Risperidone is reported as an ingredient of Riscord in the following countries:
International Drug Name Search
Rewodina may be available in the countries listed below.
Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Rewodina in the following countries:
International Drug Name Search
Dentargle F may be available in the countries listed below.
Neomycin sulfate (a derivative of Neomycin) is reported as an ingredient of Dentargle F in the following countries:
International Drug Name Search
Generic Name: terbutaline (Oral route)
ter-BUE-ta-leen
In the U.S.
Available Dosage Forms:
Therapeutic Class: Bronchodilator
Pharmacologic Class: Sympathomimetic
Terbutaline is used to prevent bronchospasm in patients 12 years of age and older with asthma, bronchitis, emphysema, and other lung diseases.
Terbutaline belongs to the family of medicines known as bronchodilators. Bronchodilators are medicines that relax the muscles in the bronchial tubes (air passages) of the lungs. They relieve cough, wheezing, shortness of breath, and troubled breathing by increasing the flow of air through the bronchial tubes.
This medicine is available only with your doctor's prescription.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Use of terbutaline in children younger than 12 years of age is not recommended.
No information is available on the relationship of age to the effects of terbutaline in geriatric patients.
| Pregnancy Category | Explanation | |
|---|---|---|
| All Trimesters | B | Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate studies in pregnant women OR animal studies have shown an adverse effect, but adequate studies in pregnant women have failed to demonstrate a risk to the fetus. |
Studies in women suggest that this medication poses minimal risk to the infant when used during breastfeeding.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:
Take this medicine exactly as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered. Do not change or stop using this medicine without checking first with your doctor.
You may be taking other medicines for asthma together with terbutaline. Do not stop taking these medicines and do not reduce the dose, even if your asthma seems better, unless you are told to do so by your doctor.
The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
Ask your healthcare professional how you should dispose of any medicine you do not use.
It is very important that your doctor check the progress of you or your child at regular visits. This will allow your doctor to see if the medicine is working properly and to check for any unwanted effects.
Using this medicine to prevent or treat preterm labor can harm pregnant women. This medicine may increase risk of heart problems and other serious side effects when given to a pregnant woman for a long time. Use an effective form of birth control to keep from getting pregnant. If you think you have become pregnant while using the medicine, tell your doctor right away.
Check with your doctor at once if difficulty with breathing continues after using a dose of this medicine or if your condition gets worse.
You may also be taking an anti-inflammatory medicine (e.g., corticosteroids) for asthma along with this medicine. Do not stop taking the anti-inflammatory medicine even if your asthma seems better, unless you are told to do so by your doctor.
If you develop a skin rash, hives, or any allergic reaction to this medicine, stop using the medicine and check with your doctor right away.
Hypokalemia may occur with this medicine. Check with your doctor right away if you or your child have more than one of the following symptoms: convulsions; decreased urine; dry mouth; increased thirst; irregular heartbeat; loss of appetite; mood changes; muscle pain or cramps; nausea or vomiting; numbness or tingling in the hands, feet, or lips; shortness of breath; or unusual tiredness or weakness.
Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines for appetite control, asthma, colds, cough, hay fever, or sinus problems, and herbal or vitamin supplements.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur:
Get emergency help immediately if any of the following symptoms of overdose occur:
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
See also: Brethine side effects (in more detail)
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
Nicobita E may be available in the countries listed below.
Tocopherol, α- nicotinate (a derivative of Tocopherol, α-) is reported as an ingredient of Nicobita E in the following countries:
International Drug Name Search
Mitomicina Mitolem may be available in the countries listed below.
Mitomycin is reported as an ingredient of Mitomicina Mitolem in the following countries:
International Drug Name Search
Alprazolam A may be available in the countries listed below.
Alprazolam is reported as an ingredient of Alprazolam A in the following countries:
International Drug Name Search
Rexner may be available in the countries listed below.
Ciprofloxacin hydrochloride (a derivative of Ciprofloxacin) is reported as an ingredient of Rexner in the following countries:
International Drug Name Search
Pan-Gentamicine may be available in the countries listed below.
Gentamicin is reported as an ingredient of Pan-Gentamicine in the following countries:
International Drug Name Search
Generic Name: docusate (DOK ue sate)
Brand Names: Calcium Stool Softener, Colace, Correctol Softgel Extra Gentle, D-S Caps, Diocto, Doc-Q-Lace, Docu, Docu Soft, Doculase, Docusoft S, DocuSol, DOK, DOS, DSS, Dulcolax Stool Softener, Enemeez Mini, Fleet Sof-Lax, Kao-Tin, Kaopectate Stool Softener, Kasof, Phillips Stool Softener, Silace, Sur-Q-Lax
Docusate is a stool softener. It makes bowel movements softer and easier to pass.
Docusate is used to treat or prevent constipation, and to reduce pain or rectal damage caused by hard stools or by straining during bowel movements.
Docusate may also be used for other purposes not listed in this medication guide.
Ask a doctor or pharmacist before using docusate if you are on a low-salt diet, if you are pregnant or breast-feeding, or if you have recently had a sudden change in your bowel habits lasting for longer than 2 weeks.
Ask a doctor or pharmacist if it is safe for you to take docusate:
if you are on a low-salt diet; or
if you have recently had a sudden change in your bowel habits lasting for longer than 2 weeks.
Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended.
Measure liquid medicine with a special dose-measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one. Mix the liquid with 6 to 8 ounces of milk, fruit juice, or infant formula and drink the mixture right away.
Try to empty your bowel and bladder just before using the enema.
Twist off the applicator tip. Lie down on your left side with your knees bent, and gently insert the tip of the enema applicator into the rectum. Squeeze the tube to empty the entire contents into the rectum. Throw away the tube, even if there is still some medicine left in it.
After using docusate, you should have a bowel movement within 12 to 72 hours. Call your doctor if you have not had a bowel movement within 1 to 3 days.
Since docusate is used as needed, you may not be on a dosing schedule. If you are using the medication regularly, use the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not use extra medicine to make up the missed dose.
Overdose symptoms may include nausea, vomiting or stomach pain.
Avoid using the bathroom just after using docusate enema.
rectal bleeding or irritation;
numbness or a rash around your rectum;
severe diarrhea or stomach cramps; or
continued constipation.
Less serious side effects may include:
mild diarrhea; or
mild nausea.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
There may be other drugs that can interact with docusate. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
See also: DOK side effects (in more detail)
Petidina Clorhidrato may be available in the countries listed below.
Pethidine hydrochloride (a derivative of Pethidine) is reported as an ingredient of Petidina Clorhidrato in the following countries:
International Drug Name Search
Indomet may be available in the countries listed below.
Indometacin is reported as an ingredient of Indomet in the following countries:
International Drug Name Search
Bigsens may be available in the countries listed below.
Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Bigsens in the following countries:
International Drug Name Search
Nicorette Kaudepot may be available in the countries listed below.
Nicotine resinate (a derivative of Nicotine) is reported as an ingredient of Nicorette Kaudepot in the following countries:
International Drug Name Search
Hexamycin may be available in the countries listed below.
Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Hexamycin in the following countries:
International Drug Name Search
DBL Dobutamine may be available in the countries listed below.
Dobutamine hydrochloride (a derivative of Dobutamine) is reported as an ingredient of DBL Dobutamine in the following countries:
International Drug Name Search
Remecilox may be available in the countries listed below.
Ofloxacin is reported as an ingredient of Remecilox in the following countries:
International Drug Name Search
Telazine may be available in the countries listed below.
Trifluoperazine hydrochloride (a derivative of Trifluoperazine) is reported as an ingredient of Telazine in the following countries:
International Drug Name Search
Duplat may be available in the countries listed below.
Pentoxifylline is reported as an ingredient of Duplat in the following countries:
International Drug Name Search
Apo-Trimebutine may be available in the countries listed below.
Trimebutine maleate (a derivative of Trimebutine) is reported as an ingredient of Apo-Trimebutine in the following countries:
International Drug Name Search
Calsenate may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Edetic Acid calcium disodium salt (a derivative of Edetic Acid) is reported as an ingredient of Calsenate in the following countries:
International Drug Name Search
Revia Gervasi Farmacia may be available in the countries listed below.
Naltrexone hydrochloride (a derivative of Naltrexone) is reported as an ingredient of Revia Gervasi Farmacia in the following countries:
International Drug Name Search
Veroxil may be available in the countries listed below.
Indapamide is reported as an ingredient of Veroxil in the following countries:
Lisinopril dihydrate (a derivative of Lisinopril) is reported as an ingredient of Veroxil in the following countries:
International Drug Name Search
Pravastatin-saar may be available in the countries listed below.
Pravastatin sodium salt (a derivative of Pravastatin) is reported as an ingredient of Pravastatin-saar in the following countries:
International Drug Name Search
Gen-Atenolol may be available in the countries listed below.
Atenolol is reported as an ingredient of Gen-Atenolol in the following countries:
International Drug Name Search
Class: Azoles
ATC Class: G01AF17
VA Class: DE102
Chemical Name: 1-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-yl)ethanone (Z)-O-[(2,4-Dichlorophenyl)methyl]oxime mononitrate
Molecular Formula: C18H13C14N3O•HNO3
CAS Number: 64211-46-7
Brands: Oxistat
Antifungal; azole (imidazole derivative).1 2 3 7 8 9 11 12 14 20 27 34 43
Treatment of tinea corporis (body ringworm)1 20 24 25 28 and tinea cruris (jock itch)1 20 24 25 caused by Epidermophyton floccosum,1 20 25 27 28 Microsporum canis†,20 25 27 28 M. gypseum†,25 Trichophyton mentagrophytes,1 20 25 27 28 T. rubrum,1 20 25 27 28 or T. verrucosum†.20 28
Treatment of tinea pedis1 20 24 25 or tinea manuum†24 25 caused by E. floccosum,20 25 27 28 M. canis†,20 25 27 28 M. gypseum†,25 T. mentagrophytes,1 20 25 27 28 T. rubrum,1 20 25 27 28 or T. verrucosum†.20 28
Topical antifungals usually effective for treatment of uncomplicated tinea corporis or tinea cruris.35 36 39 40 41 An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy.35 36 39 40 41
Topical antifungals usually effective for treatment of uncomplicated tinea pedis or tinea manuum.36 39 41 An oral antifungal may be necessary for treatment of hyperkeratotic areas on the palms and soles, for chronic moccasin-type (dry-type) tinea pedis, and for tinea unguium (fingernail or toenail dermatophyte infections, onychomycosis).36 41
Treatment of pityriasis (tinea) versicolor caused by Malassezia furfur (Pityrosporum orbiculare or P. ovale).1
Topical antifungals usually effective; an oral antifungal (with or without a topical antifungal) may be necessary in patients who have extensive or severe infections or failed to respond to or have frequent relapses with topical therapy.37 38 40
Treatment of cutaneous candidiasis† caused by Candida albicans or C. tropicalis.27 28
Apply topically to the skin as a 1% cream or lotion.1
Do not apply to the eye1 or administer intravaginally.1 32 33
Avoid contact with the nose, mouth, and other mucous membranes.1
Do not use with occlusive dressings or wrappings, unless otherwise directed by clinician.1
Shake lotion well before using.1
Apply a sufficient amount of cream or lotion; rub gently into affected area and immediately surrounding healthy skin.1
Available as oxiconazole nitrate; dosage expressed in terms of oxiconazole.1
Apply 1% cream once or twice daily for 2 weeks.1
If clinical improvement does not occur after treatment, reevaluate diagnosis.1
Apply 1% cream once or twice daily for 1 month.1
If clinical improvement does not occur after treatment, reevaluate diagnosis.1
Apply 1% cream once daily for 2 weeks.1
If clinical improvement does not occur after treatment, reevaluate diagnosis.1
Normalization of hyper- or hypopigmented patches on trunk, neck, arms, and upper thighs is variable and may take months.1
Apply 1% cream or lotion once or twice daily for 2 weeks.1
If clinical improvement does not occur after treatment, reevaluate diagnosis.1
Apply 1% cream or lotion once or twice daily for 1 month.1
If clinical improvement does not occur after treatment, reevaluate diagnosis.1
Apply 1% cream once daily for 2 weeks.1
If clinical improvement does not occur after treatment, reevaluate diagnosis.1
Normalization of hyper- or hypopigmented patches on trunk, neck, arms, and upper thighs is variable and may take months.1
No special population dosage recommendations at this time.1
Known hypersensitivity to oxiconazole or any ingredient in the formulation.1
For external use only.1 Use only for topical application to the skin; not for ophthalmic1 or intravaginal use.1 32 33
Contact dermatitis reported following topical application of oxiconazole or other imidazole-derivative azole antifungals.1 21 22 47
If irritation or sensitivity occurs, discontinue the drug and initiate appropriate therapy.1
Possible cross-sensitization among the imidazoles.21 22 44 45 46 47 48
Category B.1
Distributed into milk; caution if used in nursing women.1 32
Cream may be used in pediatric patients; has been used in children ≤10 years of age without unusual adverse effect.1
Safety and efficacy of lotion not established in children.1
Insufficient experience in patients ≥65 years of age to determine whether safety and efficacy differ from that in younger adults.1
Available data to date indicate no difference in safety compared with younger adults; dosage adjustment not recommended.1
Pruritus, burning, irritation, stinging.1
No formal drug interaction studies to date.1
Only low concentrations absorbed systemically following topical application to skin.1
Topical application to skin results in highest concentrations in epidermis and lower concentrations in upper and deeper corneum.1 In vitro on animal skin, oxiconazole 1% cream was retained in the horny layer of the epidermis for up to 96 hours after topical application.10 20
Distributed into milk.1 32
Not known whether systemically absorbed oxiconazole crosses the placenta.32 33
Systemically absorbed drug excreted in urine (<0.3% of topical dose).1
15–30C;1 cream is stable for 24 months after the date of manufacture.32
Imidazole-derivative azole antifungal.1 2 3 7 8 9 11 12 14 20 27 34 43
Usually fungistatic;3 7 8 34 may be fungicidal at high concentrations or against very susceptible organisms.3 7 34
Presumably exerts its antifungal activity by altering cellular membranes, resulting in increased membrane permeability, secondary metabolic effects, and growth inhibition.3 4 5 9 Fungistatic activity may result from interference with ergosterol synthesis.1 4 5 9 34
Spectrum of antifungal activity includes many fungi, including yeasts and dermatophytes.1 2 3 7 11 12 14 20 34 Also has in vitro activity against some gram-positive bacteria.3 20
Dermatophytes: Active in vitro against Epidermophyton floccosum,1 3 7 Microsporum audouinii,1 7 M. canis,1 2 3 7 M. gypseum,1 3 7 Trichophyton mentagrophytes,1 2 3 6 7 16 T. rubrum,1 2 3 7 T. tonsurans,1 7 and T. violaceum.1
Candida: Active in vitro against Candida albicans,1 2 3 11 12 16 C. glabrata (Torulopsis glabrata),2 3 11 C. guilliermondii,3 C. krusei,2 3 C. parapsilosis,2 3 11 and C. tropicalis.2 3
Other fungi: Active in vitro against Malassezia furfur (Pityrosporum orbiculare).1 7 Also active in vitro against Aspergillus flavus,2 3 11 A. fumigatus,2 3 11 A. nidulans,3 A. niger,3 Cryptococcus neoformans,3 11 Epidermophyton floccosum,1 3 7 Exophiala werneckii,7 Petriellidium boydii,11 and Sporothrix schenkii.11
Bacteria: Active in vitro against Actinomadura madurae,3 Corynebacterium minutissimum,20 Nocardia asteroides,3 N. brasiliensis,3 and Streptomyces somaliensis.3
Cross-resistance can occur among the azole antifungals.7 32 Some C. albicans resistant to ketoconazole show cross-resistance to oxiconazole and other imidazole-derivative antifungals as well as to triazole derivatives.32
Some strains of M. furfur (Pityrosporum orbiculare) resistant to oxiconazole in vitro are cross-resistant to econazole.7
Importance of completing full course of treatment, even if symptoms improve.1
Importance of contacting clinician if skin condition worsens during therapy or if improvement does not occur after completing full course of therapy.1
Importance of applying to affected areas as directed and avoiding contact with eyes, nose, mouth, or mucous membranes.1
Importance of not using occlusive dressings, unless otherwise directed by clinician.1
Importance of washing hands after applying oxiconazole.1
Importance of discontinuing use and contacting clinician if treated area becomes irritated (e.g., itching, burning, blistering, swelling, oozing).1 32 33
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.1
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1
Importance of informing patients of other important precautionary information.1 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Topical | Cream | 1% (of oxiconazole) | Oxistat (with benzoic acid and propylene glycol) | GlaxoSmithKline |
Lotion | 1% (of oxiconazole) | Oxistat (with benzoic acid and propylene glycol) | GlaxoSmithKline |
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Oxistat 1% Cream (PHARMADERM): 30/$94.99 or 90/$275.98
Oxistat 1% Cream (PHARMADERM): 60/$169.99 or 180/$479.98
Oxistat 1% Lotion (PHARMADERM): 30/$102.19 or 90/$300.06
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions July 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
1. GlaxoSmithKline Consumer Healthcare LP. Oxistat (oxiconazole nitrate) cream and lotion 1% prescribing information. Pittsburgh, PA; 2002 Aug.
2. Odds FC, Webster CE, Abbott AB. Antifungal relative inhibition factors: BAY I-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14- 4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. J Antimicrob Chemother. 1984; 14:105-14. [PubMed 6094418]
3. Polak A. Oxiconazole, a new imidazole derivative: evaluation of antifungal activity in vitro and in vivo. Arzneimittelforschung. 1982; 32:17-24. [PubMed 7037014]
4. Odds FC, Cheesman SL, Abbott AB. Suppression of ATP in Candida albicans by imidazole and derivative antifungal agents. Sabouraudia. 1985; 23:415-24. [PubMed 3913012]
5. Polak-Wyss A, Lengsfeld H, Oesterhelt G. Effect of oxiconazole and Ro 14-4767/002 on sterol pattern in Candida albicans. Sabouraudia. 1985; 23:433-42. [PubMed 3913013]
6. Hanel H, Raether W, Dittmar W. Evaluation of fungicidal action in vitro and in a skin model considering the influence of penetration kinetics of various standard antimycotics. Ann NY Acad Sci. 1988; 544:329-37. [PubMed 3214073]
7. Shadomy S, Wang H, Shadomy HJ. Further in vitro studies with oxiconazole nitrate. Diagn Microbiol Infect Dis. 1988; 9:231-7. [PubMed 3180708]
8. Beggs WH. Influence of growth phase on the susceptibility of Candida albicans to butoconazole, oxiconazole, and sulconazole. J Antimicrob Chemother. 1985; 16:397-9. [PubMed 3902762]
9. Hay RJ. Recent advances in the management of fungal infections. Q J Med. 1987; 64:631-9. [IDIS 236127] [PubMed 3328211]
10. Polak A. Antifungal activity of four antifungal drugs in the cutaneous retention time test. Sabouraudia. 1984; 22:501-3. [PubMed 6523308]
11. Gebhart RJ, Espinel-Ingroff A, Shadomy S. In vitro susceptibility studies with oxiconazole (Ro 13-8996). Chemotherapy. 1984; 30:244-7. [IDIS 187989] [PubMed 6086246]
12. Mallie M, Jouvert S, Bastide M et al. Activité comparée de huit composés azolés sur Candida albicans: pouvoir fongistatique et cytologie en microscopie électronique a balayage. Pathol Biol. 1988; 36:575-80. [PubMed 3043361]
13. Garuti L, Giovanninetti G, Ferranti A et al. Synthesis and antimycotic activity of some benzyloxyimino compounds. Pharmazie. 1987; 42:378-81. [PubMed 3671457]
14. Kerridge D. Mode of action of clinically important antifungal drugs. Adv Microbiol Physiol. 1986; 27:1-72.
15. Timm U, Zell M, Herzfeld L. Sensitive gas-liquid chromatographic method for the determination of oxiconazole in plasma. J Chromatogr. 1982; 229:111-20. [PubMed 7085818]
16. Dittmar W, Jovic N. Laboratory techniques alternative to in vivo experiments for studying the liberation, penetration and fungicidal action of topical antimycotic agents in the skin, including ciclopiroxolamine. Mykosen. 1987; 30:326-42. [PubMed 3657856]
17. Walters KA. Penetration of chemicals into, and through, the nail plate. Pharm Int. 1985; 6:86-9.
18. Stuttgen G, Bauer E. Permeation of labelled oxiconazole: comparison between the autoradiographic and the horizontal-slice technique in human skin. Mykosen. 1985; 28:138-47. [PubMed 3990703]
19. Stuttgen G, Bauer E. Bioavailability, skin- and nail penetration of topically applied antimycotics. Mykosen. 1982; 25:74-80. [PubMed 7062934]
20. Ramelet AA, Walker-Nasir E. One daily application of oxiconazole cream is sufficient for treating dermatomycoses. Dermatologica. 1987; 175:293-5. [PubMed 3319722]
21. Raulin C, Frosch PJ. Contact allergy to imidazole antimycotics. Contact Dermatitis. 1988; 18:76-80. [PubMed 2966706]
22. Raulin C, Frosch PJ. Contact allergy to oxiconazole. Contact Dermatitis. 1987; 16:39-40. [PubMed 3816206]
23. Gouveia DC, Jones da Silva C. Oxiconazole in the treatment of vaginal candidiasis: single dose versus 3-day treatment with econazole. Pharmatherapeutica. 1984; 3:682-5. [PubMed 6463068]
24. Wagner W. Comparison of clinical efficacy and tolerability of oxiconazole, one dose versus two doses daily. Mykosen. 1986; 29:280-4. [PubMed 3762589]
25. Arreaza de Arreaza F, De Torres ED, Maaz TB. Estudio comparativo doble ciego de RO-13-8996 con miconazole en relacion a su eficacia y tolerancia local en pacientes con dermatomicosis. Med Cutan Ibero Lat Am. 1984; 12:57-61. [PubMed 6376980]
26. Cetera C. Trattamento della candidiasi vaginale con un nuovo derivato imidazolico, l’oxiconazolo. Boll Chim Farm. 1985; 124(Suppl):13-20S. [PubMed 4015863]
27. Gip L. Comparison of oxiconazole (Ro 13-8996) and econazole in dermatomycoses. Mykosen. 1984; 27:295-302. [PubMed 6382000]
28. Wagner W, Reckers-Czaschka R. Oxiconazole in dermatomycosis: a double-blind, randomized comparison with bifonazol. Mykosen. 1987; 30:484-92. [PubMed 3325843]
29. Vanden Bossche H, Lauwers W, Willemsens G et al. Molecular basis for the antimycotic and antibacterial activity of N-substituted imidazoles and triazoles: the inhibition of isoprenoid biosynthesis. Pestic Sci. 1984; 15:188-98.
30. Thomas AH. Suggested mechanisms for the antimycotic activity of the polyene antibiotics and the N-substituted imidazoles. J Antimicrob Chemother. 1986; 17:269-79. [PubMed 3516967]
31. Sud IJ, Feingold DS. Mechanisms of action of the antimycotic imidazoles. J Invest Dermatol. 1981; 76:438-41. [IDIS 133194] [PubMed 7017013]
32. Vonderweidt J (Glaxo Inc, Research Triangle Park, NC): Personal communication; 1989 Jul 14.
33. Reviewers’ comments (personal observations); 1989 Jul.
34. Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev. 1988; 1:187-217. [PubMed 3069196]
35. Gupta AK, Einarson TR, Summerbell RC et al. An overview of topical antifungal therapy in dermatomycoses: a North American perspective. Drugs. 1998; 55:645-74. [PubMed 9585862]
36. Piérard GE, Arrese JE, Piérard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs. 1996; 52:209-24. [PubMed 8841739]
37. Sunenshine PJ, Schwartz RA, Janniger CK. Tinea versicolor: an update. Cutis. 1998; 61:65-72. [PubMed 9515210]
38. Assaf RR, Weil ML. The superficial mycoses. Dermatol Clin. 1996; 14:57-67. [PubMed 8821158]
39. Lesher JL. Recent developments in antifungal therapy. Dermatol Clin. 1996; 14:163-9. [PubMed 8821170]
40. Hay RJ. Dermatophytosis and other superficial mycoses. In: Mandel GL, Douglas RG Jr, Bennett JE, eds. Principles and practices of infectious disease. 4th ed. New York: Churchill Livingston; 1995: 2375-86.
41. Drake LA, Dincehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. J Am Acad Dermatol. 1996; 34:282-6. [IDIS 363962] [PubMed 8642094]
42. Drake LA, Dinehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. J Am Acad Dermatol. 1996; 34:287-9. [IDIS 363963] [PubMed 8642095]
43. Reviewers’ comments (personal observations) on Sulconazole 84:04.08.
44. Bigardi AS, Pigatto PD, Altomare G. Allergic contact dermatitis due to sulconazole. Contact Dermatitis. 1992; 26:281-2. [PubMed 1395584]
45. Machet L, Vaillant L, Muller C et al. Contact dermatitis and cross-sensitivity from sulconazole nitrate. Contact Dermatitis. 1992; 26:352-3. [PubMed 1395603]
46. Jones SK, Kennedy CTC. Contact dermatitis from tioconazole. Contact Dermatitis. 1990; 22:122-3. [PubMed 2138969]
47. Baes H. Contact sensitivity to miconazole with ortho-chloro cross-sensitivity to other imidazoles. Contact Dermatitis. 1991; 24:89-93. [PubMed 1828223]
48. Marren P, Powell S. Contact sensitivity to tioconazole and other imidazoles. Contact Dermatitis. 1992; 27:129-30. [PubMed 1395626]
Canrenoate Potassium may be available in the countries listed below.
Canrenoate Potassium (USAN) is also known as Potassium Canrenoate (Rec.INN)
International Drug Name Search
Glossary
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Remodellin may be available in the countries listed below.
Alfacalcidol is reported as an ingredient of Remodellin in the following countries:
International Drug Name Search
Reforgan may be available in the countries listed below.
Arginine aspartate (a derivative of Arginine) is reported as an ingredient of Reforgan in the following countries:
International Drug Name Search
Tropimil may be available in the countries listed below.
Tropicamide is reported as an ingredient of Tropimil in the following countries:
International Drug Name Search
Gemcitabin SUN may be available in the countries listed below.
Gemcitabine hydrochloride (a derivative of Gemcitabine) is reported as an ingredient of Gemcitabin SUN in the following countries:
International Drug Name Search
Vennaxa may be available in the countries listed below.
Venlafaxine hydrochloride (a derivative of Venlafaxine) is reported as an ingredient of Vennaxa in the following countries:
International Drug Name Search
Acétate de Cyprotérone Arrow may be available in the countries listed below.
Cyproterone 17α-acetate (a derivative of Cyproterone) is reported as an ingredient of Acétate de Cyprotérone Arrow in the following countries:
International Drug Name Search
Vijomikin may be available in the countries listed below.
Amikacin sulfate (a derivative of Amikacin) is reported as an ingredient of Vijomikin in the following countries:
International Drug Name Search
Acespargin may be available in the countries listed below.
Potassium Acetylhydroaspartate is reported as an ingredient of Acespargin in the following countries:
International Drug Name Search
Lampren may be available in the countries listed below.
Clofazimine is reported as an ingredient of Lampren in the following countries:
International Drug Name Search
Retiblan may be available in the countries listed below.
Retinol is reported as an ingredient of Retiblan in the following countries:
International Drug Name Search